
IGM Biosciences, Inc. (NASDAQ: IGMS) related to its merger to Concentra Biosciences, LLC for $1.247 in cash per share of IGM Biosciences common stock, plus one non-tradeable contingent value right, which represents the right to receive: (i) 100% of the closing net cash of IGM Biosciences in excess of $82.0 million; and (ii) 80% of any net proceeds received within one year following closing from any disposition of certain of IGM Biosciences’ product candidates and intellectual property that occurs within one year following closing.